| BUSINESS STRATEGY |
Co.'s primary focus is on using its core, proprietary technology to develop a cell transplant therapy for treatment of Type 1 diabetes. There is a large patient population suffering from Type 1 diabetes and even with life long insulin treatments the consequences of the disease are devastating to the patient and very costly for health care systems. Furthermore, replacement cell transplantation is known to be highly effective in treatment of Type 1 diabetes. Co. intends to complete the research phase of development of its RTM cell treatment for Type 1 diabetes in collaboration with leaders in the field. Then Co. will secure financing for clinical evaluation of the product and market either independently or with a strategic partner. Co.'s business model includes initial marketing directed specifically at the established Juvenile Diabetes Transplant Centers throughout the U.S. Co. will request that physicians at these centers remove a small tissue (SKIN) biopsy from the patient. At an adjacent Co. Transdifferentiation Center, the patient's cells will be immediately reprogrammed. After an overnight culture and selection, the cells will return to the center for immediate transplantation into the patient |
| UPDATE | 05.02 |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |